Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 24, 2008 Brian Orelli	Illumina Polishes Its Biochips There's very little to complain about in Illumina's earnings report. In this market, you'll see few investors grumbling about double-digit growth.
The Motley Fool February 6, 2008 Brian Orelli	Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward?
The Motley Fool January 11, 2008 Brian Orelli	Biochip Packaging: Some Settling May Occur Biochip maker Illumina settles its disputes about patents with Affymetrix.
The Motley Fool February 8, 2010 Brian Orelli	An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement.
The Motley Fool April 24, 2008 Brian Orelli	Illumina Ignites This biochip maker is on fire.
The Motley Fool April 27, 2011 Brian Orelli	Illuminating the Growth Competition in the DNA sequencing market may be heating up, but 47% growth for Illumina isn't too shabby.
Chemistry World January 8, 2013 Andrew Turley	Illumina investment push Gene sequencing company Illumina has struck a $450 million deal to buy privately owned US firm Verinata Health, which specializes in non-invasive tests for early identification of fetal chromosomal abnormalities.
The Motley Fool October 24, 2007 Brian Orelli	Illumina's Illuminating Results There was stellar revenue growth, but margins and stock compensations pulled the bottom line down.
Chemistry World November 21, 2013 Phillip Broadwith	Rapid DNA sequencing cleared for the clinic The approval covers Illumina's MiSeqDx instrument, together with two diagnostic assay kits for cystic fibrosis that run on it, and a kit that allows clinical labs to develop their own diagnostic tests.
The Motley Fool January 3, 2012 Alex Planes	Another Entry in the Genome Patent Rumble There's a whole lot of lawsuits going on.
The Motley Fool June 27, 2008 Brian Orelli	The Right Time to Raise Capital After seeing its stock double in less than a month, thanks to some stellar preliminary results from its prenatal Down syndrome test, diagnostic-test maker Sequenom figured now was a perfect time to get some money into the coffers.
The Motley Fool April 22, 2009 Brian Orelli	Illuminating Stock Option Problems Illumina's stock options are getting a little ridiculous. This problem was pointed out in the third quarter last year, and it doesn't seem to be going away.
The Motley Fool April 25, 2008 Brian Orelli	Affymetrix Learns About Inertia Slower sales of its older chips drag down growth.
The Motley Fool August 12, 2009 Brian Orelli	The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing.
The Motley Fool November 12, 2008 Brian Orelli	Affymetrix Gets Specific The biochip maker announces that it will acquire privately held Panomics for $73 million in cash.
The Motley Fool October 22, 2008 Jim Mueller	Illuminating Illumina Did the DNA analysis equipment maker miss, meet, or beat expectations? Well, it's complicated.
The Motley Fool May 28, 2010 Brian Orelli	Is It Time to Make Money Investing in Genetic Testing? Easier said than done.
The Motley Fool February 4, 2009 Brian Orelli	43% Growth! Yee-Haw! Illumina rocks another quarter.
Chemistry World August 22, 2014 Phillip Broadwith	Illumina targets cancer diagnostics Genetic sequencing heavyweight Illumina has partnered with three major pharmaceutical firms in a bid to develop a universal sequencing-based oncology test system.
The Motley Fool October 28, 2009 Brian Orelli	Ugly, but Still Built for Growth It continues to be a tale of two business segments for Illumina, with sales from the consumables used in its sequencing machines more than doubling, while its array business remains down considerably.
The Motley Fool April 27, 2007 Brian Orelli	Making Money Off Your Competitors Affymetrix is looking appealing with a few new products and potential revenues from an unlikely source. Investors, take note.
The Motley Fool June 14, 2010 Bruce Bigelow	Genetic Testing Companies in San Diego, Boston, and San Francisco Studying FDA Letters The letters notify the companies that genome-sequencing tests they offer to consumers are medical devices that require the agency's approval.
The Motley Fool October 25, 2007 Brian Orelli	Turnaround at Affymetrix Affymetrix announces it is continuing its turnaround from an abysmal 2006 with another strong quarter.
BusinessWeek February 20, 2006 Gene G. Marcial	Fast Growth At Illumina Is In The Genes The company has become a rising star in the complex analysis of gene variation, and the stock shows it.
Chemistry World January 27, 2012 Sarah Houlton	Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach.
The Motley Fool October 24, 2008 Brian Orelli	Affymetrix Has Trouble Turning Around The problem is that Affymetrix doesn't sell sequencers, and no one seems to want the genome and RNA analyzers that it does sell.
The Motley Fool July 28, 2010 Brian Orelli	Now There's an Illuminating Idea Helping your customers sell more of your product makes a lot of sense.
The Motley Fool July 25, 2007 Brian Orelli	Shiny Happy Illumina Illumina, which makes chips that can distinguish one million different genes, announced another stellar quarter. That makes eight in a row.
The Motley Fool September 27, 2007 Brian Orelli	Foreign Invasion of the Biochip Market A consortium of Japanese companies including Toshiba, and Canon are planning on jointly developing biochips for research and diagnostic purposes.
The Motley Fool July 22, 2009 Brian Orelli	Levering the Genome Lower revenue can't stop Illumina from turning in a good bottom line.
Bio-IT World February 2007 Robert M. Frederickson	Scramble for CodeLink Customers GE Healthcare has quietly announced that it will stop production of the popular CodeLink array system in 2007. The news was not a complete surprise to some users of the system who felt the company had been backing away from the platform.
The Motley Fool September 24, 2008 Brian Orelli	100% Results From Sequenom The company presents more data on its molecular diagnostic and buys a lab to run the tests in.
The Motley Fool July 25, 2008 Brian Orelli	Affymetrix Astounds, in the Worst Way After taking a beating last quarter, biochip maker Affymetrix got pounded again in the second quarter, as its turnaround from the lows of 2006 fizzled out.
The Motley Fool August 25, 2009 Brian Orelli	That's How You Want to Spend Investors' Money? A high-growth buyback? Really? On the surface, the buyback of Illumina shares looks like a pretty poor use of capital, but in truth, the move might not be that bad for investors.
The Motley Fool January 14, 2010 Brian Orelli	$1,000 Genomes, Here We Come Illumina jumps on news of its $10,000 genome.
The Motley Fool July 26, 2007 Brian Orelli	Affymetrix Advances New products and services should help Affymetrix regain market share. Yesterday, the company even announced a small second-quarter profit.
The Motley Fool June 13, 2008 Brian Orelli	China Medical Passes the Test China Medical's revenue was up an impressive 74% year over year.
The Motley Fool August 7, 2006 Stephen D. Simpson	Affymetrix: Price Always Matters Affymetrix has legit technology, but that doesn't mean it has infinite value for investors.
The Motley Fool March 30, 2007 Ralph Casale	Another Genetic Sequencer Gobbled Up Roche buys out second-generation sequencer 454 Life Sciences. Investors, take note.
Bio-IT World June 2006	News Blast Spectral Spend... Nanoscale News... Testmakers...
The Motley Fool August 19, 2011 Alexander Crawford	DNA Sequencing: The Next High-Growth Market in Biotech? We compiled a list of companies with a hand in the DNA sequencing market. Should you add these companies to your watch list?
Chemistry World April 19, 2013 Sarah Houlton	Thermo Fisher to buy Life Technologies in $15.8bn deal Life Technologies specializes in research products, with a particular focus on genetic sequencing and DNA analysis.
Chemistry World May 29, 2014 Hepeng Jia	Chinese-made DNA sequencer aims to challenge foreign dominance With an independently developed next-generation DNA sequencer, Chinese scientists are aiming to challenge the dominance of international players in the world's fastest growing genome sequencing market.
The Motley Fool March 18, 2008 Brian Orelli	The Nuts and Bolts of Drug Research Merck just released a pair of papers detailing the network of proteins that are linked to obesity, but the pharmaceutical company won't benefit much financially from its studies. So who will?
The Motley Fool August 24, 2007 Brian Orelli	Take Your Medicine; Earn Your Profits Personalized medicine offers investment ideas. Let's take a look at what this new catchphrase in the medical community actually means, and how investors can benefit from it.
The Motley Fool November 17, 2006 Jack Uldrich	Neanderthal DNA Enlightens Investors Investors, the superb performance of 454's gene sequencing equipment on such a difficult and important project bodes well for its future prospects.
The Motley Fool February 13, 2009 Brian Orelli	Lynch Would Love This Company Double-digit revenue growth in this market is nothing to sneeze at, but that's what LabCorp has delivered.
The Motley Fool August 18, 2010 Luke Timmerman	Life Technologies Competes for Cheap DNA Sequencing In the race to cheaper gene sequencing.
The Motley Fool September 28, 2005 Stephen D. Simpson	Affymetrix Stumbles Again Though the company was one of the only genomics plays to escape the bubble with a real business and a solid market cap, Affymetrix's stock seemed poised to take a serious hit Wednesday for the second time in about three months.
The Motley Fool August 16, 2007 Brian Orelli	More Drugmaker Growth Without the FDA All that high-tech lab equipment has to come from somewhere. Here's how investors can benefit from it, too.